A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
← catalyst calendarSponsored by Prelude Therapeutics (industry) · PRLD — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
42actual
Sites
28
Countries
Australia, Germany, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-04 | actual | When the study began enrolling |
| Primary completion | 2026-01-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-28 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Non-small Cell Lung Carcinoma
- SMARCA4 Mutation
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastric Squamous Cell Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Squamous Cell Carcinoma
Intervention
- Drug: PRT7732
Primary outcomes
what the primary-completion date above is the date OFDose Limiting toxicity (DLT) of PRT7732
measured Baseline through Day 21
Safety and tolerability of PRT7732 as measured by incidence of DLTs
measured Baseline through completion of study, an average of 2 years
Safety and tolerability of PRT7732 as measured by incidence of laboratory deviations
measured Baseline through study completion, an average of 2 years
Safety and tolerability as measured by rates of dose modification due to AEs according to NCI CTCAE
measured Baseline through study completion, an average of 2 years
Maximum tolerated dose (MTD) of PRT7732
measured Baseline through study completion, an average of 2 years
Recommended dose for expansion (RDE) of PRT7732
measured Baseline through study completion, an average of 2 years
Permalink · PRLD's whole pipeline · Catalyst calendar · Every registered study · What changed